Senhwa Biosciences Inc (生華科) yesterday said it has partnered with the US National Institutes of Health (NIH) to evaluate the efficacy of a new drug, dubbed Silmitasertib, for treatment of COVID-19.
The drug, developed by Senhwa Biosciences to treat cancers, such as bile duct cancer, medulloblastoma and pediatric brain tumor, showed promise in human tests to curb the ribonucleic acid (RNA) virus from proliferating.
“With the attribute, the drug is expected to help combat the novel coronavirus. We have not tested the drug on patients with COVID-19 in Taiwan, but the US NIH, looking forward to the drug’s efficacy, will run some trials in the US,” Senhwa Biosciences CEO Soong Tai-sen (宋台生) said by telephone.
The company would offer the drug for free to the US agency during the tests, but it is difficult to forecast when the trials would be completed, Soong said.
The New Taipei City-based firm has no intention of running human trials for COVID-19 treatment in Taiwan, as it has put all of its resources into its clinical trials on cancer treatment, but it is willing to partner with other companies and provide its drugs for free, Soong said.
The University of California San Francisco’s Quantitative Biosciences Institute last month identified 69 drugs or experimental compounds that might be effective in treating COVID-19, including the Silmitasertib, Soong said.
Silmitasertib could promote the formation of street granules by disrupting casein kinase 2, a protein kinase that performs diverse functions related to cell survival, thus preventing viruses from gaining ingredients such as nucleic acids to create a new virus, Soong said.
“Silmitasertib offers two advantages. First, its safety has been proven during our previous tests on about 300 people for cancer treatment. And second, we have about 120kg of Simitasertib in storage in the US, which would be convenient in terms of delivery to the NIH,” he said.
Given that Silmitasertib, unlike other potential new drugs under testing for COVID-19, such as remdesivir, does not directly attack the coronavirus or reduce lung damage, it is more likely to be used as a adjuvant drug, Soong said.
However, whether it would be effective and how it would be used with other medication would be determined by the NIH, Soong said.
Silmitasertib marks the only CK2 inhibitor present in clinical trials, he said.
The drug is undergoing a few human tests, including a Phase II trial for bile duct cancer in Taiwan, the US and South Korea, a Phase II clinical trial for medulloblastoma, sponsored by the National Institute of Health-Cancer Therapy Evaluation Program and the Pediatric Brain Tumor Consortium, and a Phase I study for advanced basal cell carcinoma, it said.
Merida Industry Co (美利達) has seen signs of recovery in the US and European markets this year, as customers are gradually depleting their inventories, the bicycle maker told shareholders yesterday. Given robust growth in new orders at its Taiwanese factory, coupled with its subsidiaries’ improving performance, Merida said it remains confident about the bicycle market’s prospects and expects steady growth in its core business this year. CAUTION ON CHINA However, the company must handle the Chinese market with great caution, as sales of road bikes there have declined significantly, affecting its revenue and profitability, Merida said in a statement, adding that it would
MARKET LEADERSHIP: Investors are flocking to Nvidia, drawn by the company’s long-term fundamntals, dominant position in the AI sector, and pricing and margin power Two years after Nvidia Corp made history by becoming the first chipmaker to achieve a US$1 trillion market capitalization, an even more remarkable milestone is within its grasp: becoming the first company to reach US$4 trillion. After the emergence of China’s DeepSeek (深度求索) sent the stock plunging earlier this year and stoked concerns that outlays on artificial intelligence (AI) infrastructure were set to slow, Nvidia shares have rallied back to a record. The company’s biggest customers remain full steam ahead on spending, much of which is flowing to its computing systems. Microsoft Corp, Meta Platforms Inc, Amazon.com Inc and Alphabet Inc are
RISING: Strong exports, and life insurance companies’ efforts to manage currency risks indicates the NT dollar would eventually pass the 29 level, an expert said The New Taiwan dollar yesterday rallied to its strongest in three years amid inflows to the nation’s stock market and broad-based weakness in the US dollar. Exporter sales of the US currency and a repatriation of funds from local asset managers also played a role, said two traders, who asked not to be identified as they were not authorized to speak publicly. State-owned banks were seen buying the greenback yesterday, but only at a moderate scale, the traders said. The local currency gained 0.77 percent, outperforming almost all of its Asian peers, to close at NT$29.165 per US dollar in Taipei trading yesterday. The
The US overtaking China as Taiwan’s top export destination could boost industrial development and wage growth, given the US is a high-income economy, an economist said yesterday. However, Taiwan still needs to diversify its export markets due to the unpredictability of US President Donald Trump’s administration, said Chiou Jiunn-rong (邱俊榮), an economics professor at National Central University. Taiwan’s exports soared to a record US$51.74 billion last month, driven by strong demand for artificial intelligence (AI) products and continued orders, with information and communication technology (ICT) and audio/video products leading all sectors. The US reclaimed its position as Taiwan’s top export market, accounting for
RSS